Pegfilgrastim compared with filgrastim in patients with acute myeloid leukemia after chemotherapy

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients with acute myeloid leukemia after chemotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151020024625N8

Enrollment

Registered

2018-06-30

Start date

2017-01-20

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neutropenia. Other disorders of white blood cells

Interventions

Intervention 1: Intervention group: Patients received one or two course induction chemotherapy (idarubicin 12 mg/m2 days 1–3, cytarabine 100 mg/m2 twice daily days 1–7). If complete remission was achi

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients who went to remission after induction chemotherapy.

Exclusion criteria

Exclusion criteria: Non remission Sepsis during or after chemotherapy History of hypersensitivity reactions to E. coli-derived proteins and other drugs

Design outcomes

Primary

Measure	Time frame
Neutrophil count. Timepoint: Daily< up to 21 days after intervention. Method of measurement: Complete blood cell count and peripheral blood smear.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarahnaz Ghahremanfard MD

Semnan University of Medical Sciences

f_ghahremanfard@yahoo.com+98 23 3142 2120

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026